Microbot's LIBERTY Robot Aims to Upend Endovascular Surgery

HINGHAM, Mass. – February 19, 2026 – As medical technology continues its rapid march toward automation and precision, Microbot Medical Inc. is positioning its LIBERTY Endovascular Robotic System as a potential game-changer in vascular care. The company is amplifying its market presence this week as CEO Harel Gadot takes the stage at The Surgical Disruptive Technology Summit in Houston, a key event for showcasing innovation. The appearance comes at a pivotal moment for the company, which is transitioning from development to full commercialization, aiming to disrupt a field long dominated by high-cost, complex robotic systems.

A New Category of Surgical Robotics

At the heart of Microbot Medical's strategy is the LIBERTY system, which the company asserts is establishing a "new category of surgical robotics." This claim is built on a foundation of unique design features that distinguish it from many existing platforms. The system received its crucial 510(k) clearance from the U.S. Food and Drug Administration on September 8, 2025, marking it as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.

The pivotal study data underpinning this clearance was compelling. It demonstrated a 100% success rate in robotic navigation to target vessels and, critically, zero device-related adverse events. Perhaps one of the most significant findings was a reported 92% relative reduction in radiation exposure for the operating physician. This is a major selling point in a field where interventionalists face cumulative radiation risks over their careers.

Unlike traditional, capital-intensive robotic systems, LIBERTY is designed to be compact and disposable. Physicians operate the device remotely using a video game-style controller, manipulating guidewires and catheters from a control station, which can be situated away from the radiation source. This remote operation not only enhances safety but also introduces a new level of ergonomic comfort, moving clinicians from physically demanding, lead-apron-clad positions at the bedside to a seated, radiation-free console.

"We believe that the continued emergence of the LIBERTY System, together with the expanding range of procedures performed to date, is redefining how endovascular care is delivered today and how it will be delivered years ahead,” commented Harel Gadot, CEO, President and Chairman of Microbot Medical.

Dismantling Barriers to Robotic Adoption

The history of surgical robotics is one of remarkable innovation but also significant barriers to entry. High capital costs, which can run into the millions for a single unit, and the need for dedicated operating rooms or catheterization labs have limited the adoption of robotic technology to larger, well-funded hospital systems. Microbot Medical aims to dismantle these barriers with LIBERTY's distinct architecture.

The single-use nature of the system eliminates the substantial upfront investment in a reusable robotic console, with the company projecting potential cost savings of 30-50% compared to traditional reusable robots. This model shifts the financial burden from a massive capital expenditure to a per-procedure operational cost, a far more palatable proposition for smaller hospitals and ambulatory surgery centers. Furthermore, the disposable design completely removes the risks and costs associated with sterilizing and reprocessing complex robotic instruments.

Logistical hurdles are also addressed by the system's compact, "plug-and-play" design. The company claims the robot can be set up in under five minutes, integrating seamlessly into existing cath-lab workflows without requiring extensive infrastructure modifications. This ease of use and rapid deployment is intended to broaden access to robotic precision, potentially democratizing advanced endovascular care for a wider range of health systems and, by extension, patients.

A Calculated Path to Market

Microbot Medical is executing a carefully phased commercialization strategy. Following its FDA clearance, the company initiated a limited market release in late 2025, allowing for controlled, real-world application and feedback. The first hospital adoption for patient care was announced at Emory University Hospital, a significant early win. The company's participation in high-profile industry events like the SAGES NBT Innovation Weekend is a clear part of this strategy, designed to build momentum and educate key opinion leaders ahead of a broader launch.

The full market release is slated for the Society of Interventional Radiology (SIR) conference in April 2026. This venue provides a prime opportunity to showcase the system to a core audience of interventional radiologists, who are the primary users of such technology.

However, LIBERTY does not enter the market in a vacuum. The endovascular robotics space, while still nascent, is competitive. Siemens Healthineers previously entered the peripheral vascular intervention market before pivoting to focus on neurovascular applications, illustrating the challenges of the field. A more direct competitor is the CorPath GRX system from Corindus (a Siemens Healthineers company), which also offers remote robotic control for coronary and peripheral interventions to reduce radiation exposure. Yet, Microbot continues to emphasize LIBERTY’s unique combination of being both single-use and remotely operated for its specific peripheral indications, which it believes is a key differentiator in addressing cost and workflow barriers.

The Financial Underpinnings of Innovation

As a clinical-stage medical device company, Microbot Medical's journey is heavily dependent on its financial health. The company is currently pre-revenue, and its SEC filings reflect the significant costs associated with research, development, and pre-commercialization activities. As of its last major filing in 2025, the company held approximately $30.39 million in cash and marketable securities, a runway it is using to fund its ambitious launch plans.

Investor confidence was bolstered by the 2025 FDA clearance, a critical de-risking event. The company has also secured non-dilutive funding through a grant from the Israel Innovation Authority to support manufacturing and commercialization scale-up. Recent corporate filings detail the establishment of partnerships with third-party logistics providers, another essential step in preparing for a full-scale product launch.

The company's success now hinges on its ability to convert its technological promise and regulatory approval into market adoption and sales. "LIBERTY’s distinct advantages, including its single-use, compact robotic design, are intended to remove many of the barriers that have historically limited the broader adoption of surgical robotics," Gadot stated, expressing confidence in the system's potential. As the full market release approaches in April, the medical community and investors alike will be watching closely to see if this compact, single-use robot can truly deliver on its promise to redefine the standard of vascular care.